Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Pruritus Therapeutics Sector?

In the past few years, there has been a consistent increase in the market size of pruritus therapeutics. The market, which is forecasted to be valued at $11.89 billion in 2024, is anticipated to rise to $12.38 billion in 2025, marking a compound annual growth rate (CAGR) of 4.1%. This expansion during the historical phase is due to various factors including an uptick in pruritus cases, diverse origins and circumstances, increasing elderly populace, and emphasis on the quality of life of patients.

Significant expansion is anticipated in the pruritus therapeutics market in the coming years, with projections estimating it to reach a value of $15.7 billion by 2029, growing at a CAGR of 6.1%. This estimated growth during the forecast period can be linked to a deeper understanding of pruritus pathophysiology, advancements in drug formulations and delivery strategies, a focus on personalized medication, an upsurge in dermatological R&D, improved awareness and diagnosis rates, and a growing inclination towards botanical and herbal treatments. Predicted trends for the forecast period comprise the creation of itch-specific receptor agonists and antagonists, a market focus on personalized therapeutic strategies, the incorporation of technology in itch surveillance and treatment, and partnerships for interdisciplinary research.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

What Forces Are Driving The Growth Of The Pruritus Therapeutics Market?

The escalating incidence of skin-related ailments is predicted to bolster the expansion of the pruritus therapeutics market in the future. Dermatological disorders encompass conditions affecting the skin, hair, nails, and mucous membrane, varying from acne and eczema to skin cancer and fungal infections. How pruritus treatments are used is often dictated by the root cause of the itch in dermatological diseases. Topical treatments, emollients and moisturizers, immunosuppressive drugs, and anti-itching medications are frequently employed to treat this condition. For example, the American Cancer Society, a non-profit organization committed to eradicating cancer in the US, reported in January 2024 that there would be 108,270 skin cancer cases, a 3.2% rise from the 104,930 cases reported in 2023. Consequently, the escalating prevalence of dermatological ailments is propelling the growth of the pruritus therapeutics market.

How Is The Pruritus Therapeutics Industry Segmented Across Key Parameters?

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetics: Topical Local Anesthetics

4) By Counterirritants: Menthol-Based Products, Camphor-Based Products

5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

What Notable Trends Are Shaping The Direction Of The Pruritus Therapeutics Market?

Leading corporates in the pneumococcal vaccine sector are introducing novel products in an attempt to boost their market profits. Merck & Co Inc., an American pharmaceutical company, for instance, unveiled the V116 vaccine in July 2023. The purpose of V116 is to target the eight unique serotypes of Streptococcus pneumoniae, which are predominantly accountable for pneumococcal disease in adults. Compared with other similar vaccines, V116 has demonstrated superior immunogenicity across diverse serotypes in adult cohorts, and it has also elicited positive immune responses in both those receiving the vaccine for the first time and those who were previously immunized. The V116 has been classified as a breakthrough therapy by the U.S. Food and Drug Administration (FDA) and is currently undergoing Phase 3 trials.

Which Companies Currently Dominate The Competitive Landscape In The Pruritus Therapeutics Industry?

Major companies operating in the pruritus therapeutics market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc. , Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Escient Pharmaceuticals Inc., Nerre Therapeutic Ltd., EPI Health LLC, Trevi Therapeutics Inc., Evelo Biosciences, Toray Medical Co. Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Which Geographic Regions Are Driving Demand In The Pruritus Therapeutics Market?

North America was the largest region in the pruritus treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11907&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model